Welcome to our dedicated page for Organigram Global news (Ticker: OGI), a resource for investors and traders seeking the latest updates and insights on Organigram Global stock.
Organigram Global Inc. reports developments tied to its Canadian cannabis cultivation, processing, branded adult-use products and cannabinoid beverage business. The company operates through subsidiaries including Organigram Inc., a licensed cultivator and processor, and participates in U.S. and Canadian cannabinoid beverages through Collective Project Limited.
Recurring news themes for OGI include operating and financial results, cannabis product launches, brand extensions, international partnership activity, and regulatory matters under Health Canada’s Cannabis Act and Cannabis Regulations. Company updates also cover brands such as Edison, Big Bag O’ Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK; the FAST nanoemulsion technology platform; and production, edibles, extraction, packaging and fulfillment facilities in Canada.
Organigram (NASDAQ: OGI) reported record Q3 Fiscal 2026 results for the quarter ended June 30, 2026, driven largely by the acquisition of Sanity Group. Net revenue rose 49% year-over-year to $105.8 million, with gross revenue of $145.1 million and adjusted EBITDA increasing 136% to $13.4 million. Adjusted gross margin was $39.1 million, or 37% of net revenue, up from 34% a year earlier. Sanity Group contributed about €25 million (C$40 million) in net revenue and advanced its European growth initiatives.
Net income improved to $105.5 million versus a loss of $6.3 million in Q3 2025, mainly due to non-cash fair value gains and higher revenue. Free cash flow was an outflow of $3.9 million, and cash and short-term investments stood at $11.7 million, with total liquidity of $49.1 million. Management reiterated expectations for Fiscal 2026 net revenue to exceed $350 million and for adjusted gross margin and adjusted EBITDA to surpass Fiscal 2025 levels.
Organigram Global (NASDAQ: OGI, TSX: OGI) will report earnings results for its third quarter ended June 30, 2026 on Tuesday, August 11, 2026, prior to market open. The company will host a conference call at 8:00 a.m. Eastern Time the same day.
Investors can register for the call via Organigram’s online registration link to receive dial-in details and unique access codes. A simultaneous webcast will be available, with a replay posted within 24 hours at the company’s investor relations website and archived for 90 days.
Organigram Global (NASDAQ/TSX: OGI) issued a business update on early performance of recently acquired Sanity Group and its Canadian market position. Since closing the deal on April 15, 2026, Sanity has maintained an estimated ~10% market share in Germany and is tracking in line with revenue expectations. Organigram noted that new German rules on medical cannabis reimbursement are not expected to be material, as reimbursement accounts for about 1% of Sanity’s revenue.
In Canada, Organigram reported leading recreational market rankings: #1 in flower (12.5%), #1 in vapes (14.5%), and #2 in pre-rolls (7.3%), with strong year-over-year share gains in beverages and concentrates. Overall Canadian recreational share was 11.1% at June-end, down 0.4 percentage points year-over-year but up 100 basis points versus May. The company plans to report Q3 fiscal 2026 results around August 11, 2026, the first quarter including Sanity, and will host a Digital Investor Session in late September 2026.
Organigram (NASDAQ: OGI) reported Q2 fiscal 2026 net revenue of $59.8 million, down 9% year-over-year, and adjusted EBITDA of $0.9 million, down 82%. Net loss was $0.9 million versus prior net income of $42.5 million.
Organigram closed the acquisition of Germany’s Sanity Group, expected to add about €25 million in average quarterly revenue. Record quarterly harvest exceeded 32,000 kg (+56% YoY). Fiscal 2026 guidance now targets net revenue above $350 million and roughly break-even free cash flow.
Organigram (NASDAQ: OGI) will report second quarter fiscal 2026 results for the period ended March 31, 2026 on Tuesday, May 12, 2026, before market open.
The company will host a conference call on the same day at 8:00 am ET; registration and live webcast links are provided, and a replay will be posted within 24 hours and archived for 90 days.
Organigram (NASDAQ: OGI) closed its acquisition of Sanity Group for an upfront €107.3 million purchase price (paid as €78.0 million cash and €29.3 million in shares) pursuant to a Feb 18, 2026 share purchase agreement.
The company also closed a €40.3 million private placement/b) with BAT and secured senior secured credit facilities of up to . Max Konrad Narr was appointed to the board for the Earnout Period, and the transaction fully deployed Organigram’s Jupiter strategic investment pool.
Organigram (NASDAQ: OGI) announced that shareholders approved the acquisition of Sanity Group GmbH and a related private placement with BT DE Investments (British American Tobacco) at the March 30, 2026 annual meeting by 93% of votes cast. The Transaction includes issuance of up to 96,287,602 common shares and is expected to close in April 2026 subject to customary conditions, completion of the Private Placement and ATB Financial senior secured credit facilities. Sanity generated positive EBITDA in 2025. The deal is described as financially accretive, creating a vertically integrated European hub and expanding Organigram into the German medical cannabis market.
Organigram (NASDAQ: OGI, TSX: OGI) has mailed a management information circular for an annual and special meeting on March 30, 2026 to approve its proposed acquisition of Sanity Group GmbH.
Consideration includes an upfront €113.4 million (€80.0M cash + €33.4M in Organigram shares at $3.00 each) and an earnout of up to €113.8 million. A BAT private placement of C$65.2M is planned to fund the cash portion. Closing requires TSX approval, NASDAQ notification and German FDI clearance.
Organigram (NASDAQ: OGI) launched SHRED Shotz, a 65ml single‑serve cannabis beverage powered by its FAST™ nanoemulsion platform designed for a 15‑minute onset.
The move extends the SHRED brand—which surpassed $200 million in retail sales in 2025—into a compact format targeting taste, convenience and broader beverage occasions.
Organigram (NASDAQ:OGI) is launching Edison and BOXHOT medical vape and pastille products in Australia, introducing 10 SKUs and shipping single‑strain live terpenes from Canada. The products will distribute via Leafio, expected to reach >4,000 pharmacies, and will debut at the United in Compassion symposium Feb 26–28.
The move expands Organigram’s non‑flower portfolio into a growing Australian medical cannabis market and highlights ready‑to‑consume formats and science‑led formulations.